Table 1.

Clinicopathologic characteristics.

	OVERALL	SPORADIC	MEN1	VHL	P
	(n = 82)	(n = 37)	(n = 20)	(n = 25)
Median Age (IQR)	46 (35–60)	57 (43–63)	40 (29–49)	43 (35–53)	0.003
Gender					0.90
Male	40	19	9	12
Female	42	18	11	13
Median BMI (IQR)	30 (25–33)	22 (25–34)	29 (26–32)	31 (24–33)	0.98
Underlying Diagnosis					–
Sporadic	37	37	0	0
MEN1	20	0	20	0
VHL	25	0	0	25
VHL v Non-VHL
Non-VHL	57
VHL	25
Familial v Sporadic
Sporadic	37
Familial	45
Cystic Pancreas					< 0.001
No	62	34	18	10
Yes	20	3	2	15
Functional Tumor					< 0.001
No	37	3	9	25
Yes	45	34	11	0
History of Pancreatitis					0.19
No	79	36	18	25
Yes	3	1	2	0
History of Alcohol Abuse					0.14
No	75	35	19	21
Yes	6	1	1	4
History of Smoking					0.06
No	59	28	17	14
Yes	22	8	3	11
Pre-Op Diabetes					0.78
No	72	33	18	21
Yes	10	4	2	4
Pre-op Exocrine Replacement					–
No	82	37	20	25
Yes	0	0	0	0
Surgical Procedure					0.005
Enucleation	39	24	4	11
Distal Pancreatectomy	37	12	15	10
Pancreatiocoduodenectomy	6	1	1	4
Volume of Pancreas Resected					0.65
Mean (range)	33 cm3 (0.02–397 cm3)	28 cm3 (0.02–397 cm3)	42 cm3 (2–174 cm3)	32 cm3 (0.87–123 cm3)
Median (IQR)	18 cm3 (2–52 cm3)	2 cm3 (0.40–24 cm3)	32 cm3 (8–61 cm3)	19 cm3 (4–51 cm3)
Multifocal					0.001
No	52	31	7	14
Yes	30	6	13	11
Tumor Grade					0.16
Grade 1	43	22	12	9
Grade 2	21	5	6	10
Grade 3	2	1	0	1
Metastasis					0.22
No	70	34	15	21
Yes	12	3	5	4
Cysts in remnant pancreas					< 0.001
No	67	34	18	10
Yes	15	3	2	15
PNET in remnant pancreas					< 0.001
No	57	35	9	13
Yes	25	2	11	12
Post-op Exocrine Replacement					0.13
No	76	36	19	21
Yes	6	1	1	4
>New or Worsening Diabetes
No	72	35	16	21	0.22
Yes	10	2	4	4
Median Length of Days Follow Up (IQR)	629 (15–1894)	22 (0–177)	1454 (442–2271)	1863(648–2826)	< 0.001

MEN1: multiple endocrine neoplasia type 1,VHL: von Hippel-Lindau, PNET: pancreatic neuroendocrine tumor.

^**Three patients underwent enucleation, 5 underwent DP, and 1 underwent PD.